Dashboard
1
Company has very low debt and has enough cash to service the debt requirements
2
Poor long term growth as Net Sales has grown by an annual rate of 0.65% and Operating profit at -1.59% over the last 5 years
3
The company declared negative results in Mar'25 after flat results in Dec'24
4
With ROE of 4.35%, it has a very attractive valuation with a 0.85 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 121,215 Million (Small Cap)
19.00
NA
0.02%
-0.42
4.59%
0.92
Revenue and Profits:
Net Sales:
26,631 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,894 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
4.94%
0%
4.94%
6 Months
13.83%
0%
13.83%
1 Year
-3.68%
0%
-3.68%
2 Years
3.98%
0%
3.98%
3 Years
1.04%
0%
1.04%
4 Years
-0.87%
0%
-0.87%
5 Years
-13.27%
0%
-13.27%
Mochida Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.65%
EBIT Growth (5y)
-1.59%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.80
Tax Ratio
29.40%
Dividend Payout Ratio
49.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.13%
ROE (avg)
5.66%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
0.85
EV to EBIT
7.33
EV to EBITDA
5.38
EV to Capital Employed
0.75
EV to Sales
0.57
PEG Ratio
1.10
Dividend Yield
0.02%
ROCE (Latest)
10.22%
ROE (Latest)
4.35%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
26,631.00
25,407.00
4.82%
Operating Profit (PBDIT) excl Other Income
3,269.00
2,895.00
12.92%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
1,894.00
1,554.00
21.88%
Operating Profit Margin (Excl OI)
96.60%
86.20%
1.04%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 4.82% vs 2.67% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 21.88% vs -7.94% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
105,159.00
102,885.00
2.21%
Operating Profit (PBDIT) excl Other Income
11,067.00
8,611.00
28.52%
Interest
3.00
2.00
50.00%
Exceptional Items
0.00
-320.00
100.00%
Consolidate Net Profit
5,685.00
4,547.00
25.03%
Operating Profit Margin (Excl OI)
77.30%
56.40%
2.09%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 2.21% vs -0.36% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 25.03% vs -31.61% in Mar 2024
About Mochida Pharmaceutical Co., Ltd. 
Mochida Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






